Janux Therapeutics Inc
JANX
Company Profile
Business description
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Contact
10955 Vista Sorrento Parkway
Suite 200
San DiegoCA92130
USAT: +1 858 751-4493
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
108
Stocks News & Analysis
stocks
ASX giant falls short on copper guidance
Weak copper guidance appears temporary, but valuation concerns remain.
stocks
Pure-play data center share raises capital to fund AI demand
Funding the next wave of data center growth.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,974.70 | 32.40 | -0.36% |
| CAC 40 | 8,350.58 | 11.77 | 0.14% |
| DAX 40 | 24,884.66 | 53.68 | 0.22% |
| Dow JONES (US) | 52,146.42 | 406.55 | -0.77% |
| FTSE 100 | 10,557.65 | 42.72 | -0.40% |
| HKSE | 25,143.05 | 580.81 | 2.36% |
| NASDAQ | 25,520.24 | 361.70 | -1.40% |
| Nikkei 225 | 64,141.12 | 2,694.42 | -4.03% |
| NZX 50 Index | 13,696.03 | 1.35 | 0.01% |
| S&P 500 | 7,457.69 | 76.08 | -1.01% |
| S&P/ASX 200 | 8,791.30 | 31.00 | -0.35% |
| SSE Composite Index | 3,796.28 | 32.13 | 0.85% |